Climb Bio Investor Relations Material
Latest events
M&A Announcement
Climb Bio
Q2 2025
12 Aug, 2025
Q1 2025
14 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Climb Bio Inc
Access all reports
Eliem Therapeutics, Inc. is a biotechnology company focused on developing therapies for neuronal excitability disorders, which are associated with conditions like chronic pain, epilepsy, depression, and anxiety. The company’s approach involves advancing clinical-stage compounds that target neurological diseases, aiming to address significant unmet medical needs. Eliem Therapeutics is headquartered in Wilmington, Delaware, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
CLYM
Country
🇺🇸 United States